col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


32 Results       Page 1

 [1] 
Publishing House OKI: Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
  original article Date Title Authors   All Authors
1 [GO] 2022―Nov―15 The use of a new oral antiviral drug molnupiravir in the treatment of COVID-19 from a safety perspective A. L. Khokhlov, J. V. Rybachkova
2 [GO] 2022―May―02 Lifestyle Changes in Medical Students during the COVID-19 Pandemic V. A. Sergeeva, T. E. Lipatova
3 [GO] 2022―Feb―14 Analysis of the effectiveness of vaccination against COVID-19 based on real-world data in St. Petersburg A. A. Kurylev, A. A. Zhuravkov, A. S. Kolbin
4 [GO] 2021―Aug―13 COVID-19: economic aspects of influenza vaccine prevention E. A. Zhidkova, E. M. Gutor, Yu. A. Tkachenko, I. V. Rogova, I. A. Popova, K. G. Gurevich
5 [GO] 2021―Mar―12 Socioeconomic and global burden of COVID-19 A. S. Kolbin, Yu. M. Gomon, Yu. E. Balykina, D. Yu. Belousov, V. V. Strizheletskiy, I. G. Ivanov
6 [GO] 2020―Oct―28 Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19 V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev
7 [GO] 2020―Oct―28 Current and future use of angiotensin II receptor blockers in patients with COVID-19 A. V. Matveev, V. A. Otdelenov, D. A. Sychev
8 [GO] 2020―Oct―28 Possibilities for the use of tofacitinib in patients with COVID-19 A. V. Matveev, Yu. Yu. Kiselev, D. A. Sychev
9 [GO] 2020―Oct―28 Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19 V. A. Otdelenov, Yu. Yu. Kiselev, K. B. Mirzaev, A. V. Matveev, D. A. Sychev
10 [GO] 2020―Oct―28 Possibilities for the use of anakinra in COVID-19 V. A. Otdelenov, A. V. Matveev, D. A. Sychev
11 [GO] 2020―Oct―28 Rationality of routine clinical use of olokizumab in COVID-19 V. M. Tsvetov, A. V. Matveev, D. A. Sychev
12 [GO] 2020―Oct―28 Current and future use of colchicine in patients with COVID-19 Yu. Yu. Kiselev, A. V. Matveev, D. A. Sychev
13 [GO] 2020―Oct―28 Current and future use of umifenovir in patients with COVID-19 Yu. Yu. Kiselev, K. A. Zagorodnikova, D. V. Ivashchenko, A. V. Krykov, I. N. Sychev, A. S. Matveev, et al. (+6)
14 [GO] 2020―Oct―28 Current and future use of vitamin D3 in patients with COVID-19 I. N. Sychev, A. V. Matveev, D. A. Sychev
15 [GO] 2020―Oct―28 Current and future use of dipyridamole in patients with COVID-19 I. S. Burashnikova, V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev
16 [GO] 2020―Oct―28 Dexamethasone use in patients with COVID-19 V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev
17 [GO] 2020―Oct―28 Current and future use of remdesivir in patients with COVID-19 V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev
18 [GO] 2020―Oct―28 Current and future use of favipiravir in patients with COVID-19 A. V. Matveev, Yu. Yu. Kiselev, D. A. Sychev
19 [GO] 2020―Oct―28 Use of unlicensed drugs and off-label drug use: focus on COVID-19 S. A. Mishinova, A. A. Zhuravkov, V. K. Zhuravko
20 [GO] 2020―Oct―28 Anticoagulant deprescribing algorithm in patients with COVID-19 after hospital discharge A. V. Krykov, V. A. Otdelenov, D. A. Sychev
21 [GO] 2020―Oct―28 Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis V. M. Tsvetov, I. N. Sychev, D. A. Sychev
22 [GO] 2020―Oct―28 Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy V. M. Tsvetov, Yu. Yu. Kiselev, K. B. Mirzaev, D. A. Sychev
23 [GO] 2020―Oct―28 Possibility to use barycytinib in patients with COVID-19, including for treatment of «cytokine storm» V. A. Otdelenov, V. M. Tsvetov, D. A. Sychev
24 [GO] 2020―Oct―28 Rationale for use mefloquine for COVID-19 treatment V. A. Otdelenov, K. B. Mirzaev, A. V. Dmitriev, V. V. Poroikov, D. A. Sychev
25 [GO] 2020―Oct―28 Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention K. B. Mirzaev, D. A. Sychev
26 [GO] 2020―Oct―28 Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab K. B. Mirzaev, Yu. Yu. Kiselev, D. A. Sychev
27 [GO] 2020―Oct―28 Is it possible to use riamilovir to prevent infection and treat COVID-19? V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev
28 [GO] 2020―Oct―28 Can inhalations of hyaluronidase be used in acute respiratory distress-syndrome in patients with COVID-19? Yu. Yu. Kiselev, K. B. Mirzaev, D. A. Sychev
29 [GO] 2020―Oct―28 Could canakinumab be used for COVID-19? V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev
30 [GO] 2020―Oct―28 Possibility for the use of bromhexine to prevent infection with SARS-CoV-2 K. A. Zagorodnikova, K. B. Mirzaev, D. A. Sychev
31 [GO] 2020―Oct―28 Possibilities for the use of hydroxychloroquine for pre- and postexposure prophylaxis of SARS-CoV-2 infection among exposed contacts and healthcare personnel V. A. Otdelenov, A. V. Krykov, D. A. Sychev
32 [GO] 2020―May―30 Socio-economic burden of COVID-19 in the Russian Federation A. S. Kolbin, D. Yu. Belousov, Yu. M. Gomon, Yu. E. Balykina, I. G. Ivanov
 [1] 

32 Results       Page 1



[de][en]

Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.006 sec